1
TITLE: European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. PLERIXAFOR IN NONHEMATOLOGIC DISEASES  Full Text
AUTHORS: Nina Worel; Jane F Apperley; Grzegorz W Basak; Kenneth W Douglas; Ian H Gabriel; Catarina Geraldes; Kai Huebel; Ozren Jaksic; Zdenek Koristek; Francesco Lanza; Roberto Lemoli; Gabor Mikala; Dominik Selleslag; Rafael F Duarte; Mohamad Mohty;
PUBLISHED: 2012, SOURCE: TRANSFUSION, VOLUME: 52, ISSUE: 11
INDEXED IN: WOS CrossRef
2
TITLE: Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF  Full Text
AUTHORS: Basak, GW; Wiktor Jedrzejczak, W; Apperley, JF; Douglas, KW; Gabriel, IH; Geraldes, C; Huebel, K; Jaksic, O; Koristek, Z; Lanza, F; Lemoli, R; Mikala, G; Selleslag, D; Worel, N; Mohty, M; Duarte, RF;
PUBLISHED: 2012, SOURCE: BONE MARROW TRANSPLANTATION, VOLUME: 47, ISSUE: 7
INDEXED IN: Scopus WOS CrossRef
3
TITLE: Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide
AUTHORS: Florent Malard; Nicolaus Kroeger; Ian H Gabriel; Kai Huebel; Jane F Apperley; Grzegorz Basak; Kenneth W Douglas; Catarina Geraldes; Ozren Jaksic; Zdenek Koristek; Francesco Lanza; Roberto M Lemoli; Gabor Mikala; Dominik Selleslag; Nina Worel; Rafael F Duarte; Mohamad Mohty;
PUBLISHED: 2011, SOURCE: 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis in BLOOD, VOLUME: 118, ISSUE: 21
INDEXED IN: WOS
4
TITLE: How cured are CML patients in complete molecular remission (CMR) after stem cell transplantation or imatinib?
AUTHORS: Manuel S Simoes ; Joannah Score; Nicholas C P Cross; Jane F Apperley; Junia V Melo;
PUBLISHED: 2007, SOURCE: 49th Annual Meeting of the American-Society-of-Hematology in BLOOD, VOLUME: 110, ISSUE: 11
INDEXED IN: WOS